Christopher J Sweeney Mbbs

List of Publications by Year
in descending order

244 papers	14,065 citations	31902 53 h-index	22764 112 g-index
246 all docs	246 docs citations	246 times ranked	14283 citing authors

#	Article	IF	Citations
1	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 2015, 373, 737-746.	13.9	2,112
2	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	13.9	982
3	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology, 2018, 36, 1080-1087.	0.8	702
4	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
5	Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. Journal of Clinical Oncology, 2013, 31, 412-419.	0.8	405
6	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology, 2018, 36, 536-542.	0.8	362
7	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2019, 20, 518-530.	5.1	362
8	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110, 4427-4435.	0.6	357
9	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3097-3104.	0.8	327
10	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
11	Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. Journal of Clinical Oncology, 2006, 24, 3451-3457.	0.8	234
12	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	0.8	229
13	Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 2019, 76, 115-124.	0.9	203
14	Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. Journal of Clinical Oncology, 2011, 29, 1525-1530.	0.8	180
15	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	5.1	178
16	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European Urology, 2018, 73, 847-855.	0.9	174
17	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet, The, 2021, 398, 131-142.	6.3	167
18	Current treatment strategies for advanced prostate cancer. International Journal of Urology, 2018, 25, 220-231.	0.5	164

#	Article	IF	Citations
19	A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2005, 11, 6625-6633.	3.2	158
20	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. European Urology, 2019, 76, 89-97.	0.9	158
21	Nuclear Factor-ÎºB Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate. Clinical Cancer Research, 2004, 10, 5501-5507.	3.2	157
22	The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Molecular Cancer Therapeutics, 2005, 4, 1004-1012.	1.9	145
23	Genomic evolution and chemoresistance in germ-cell tumours. Nature, 2016, 540, 114-118.	13.7	139
24	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: AÂsystematic review and meta-analysis. European Journal of Cancer, 2017, 84, 88-101.	1.3	128
25	Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6259-6264.	3.3	127
26	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncology, The, 2017, 18, 132-142.	5.1	124
27	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	0.8	121
28	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncology, 2015, 1, 495.	3.4	118
29	EZH2 inhibition activates a dsRNAâ€“STINGâ€“interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 444-456.	5.7	118
30	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	0.8	110
31	Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs, 2004, 22, 299-305.	1.2	109
32	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.2	109
33	Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-ÎºB pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics, 2005, 4, 587-594.	1.9	108
34	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	0.8	108
35	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 2022, 28, 144-153.	15.2	102
36	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer, 2014, 50, 3145-3152.	1.3	99

#	Article	IF	Citations
37	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	3.2	87
38	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	0.5	86
39	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	0.8	83
40	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. JAMA Oncology, 2021, 7, 544.	3.4	82
41	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1285-1291.	0.8	81
42	Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer, 2002, 94, 104-110.	2.0	79
43	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. Journal of Clinical Oncology, 2018, 36, 376-382.	0.8	75
44	A water soluble parthenolide analog suppresses in vivo tumor growth of two tobaccoâ€associated cancers, lung and bladder cancer, by targeting NFâ€ÎºB and generating reactive oxygen species. International Journal of Cancer, 2011, 128, 2481-2494.	2.3	72
45	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1088-1095.	0.8	72
46	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open, 2020, 3, e2021692.	2.8	70
47	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Optionsâ€”An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 2016, 34, 345-351.	0.8	69
48	Elevated ILâ€8, TNFâ€Îą, and MCPâ€1 in men with metastatic prostate cancer starting androgenâ€deprivation therapy (ADT) are associated with shorter time to castrationâ€resistance and overall survival. Prostate, 2014, 74, 820-828.	1.2	66
49	Association of androgenâ€deprivation therapy with excess cardiacâ€specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	1.3	66
50	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal of Clinical Oncology, 2015, 33, 3018-3028.	0.8	63
51	A waterâ€soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFÎºB and generating reactive oxygen species. Prostate, 2010, 70, 1074-1086.	1.2	60
52	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist, 2018, 23, 193-202.	1.9	60
53	Impact of ethnicity on the outcome of men with metastatic, hormoneâ€sensitive prostate cancer. Cancer, 2017, 123, 1536-1544.	2.0	57
54	â€œGotta Catch 'em Allâ€; or Do We? Pokemet Approach to Metastatic Prostate Cancer. European Urology, 2017, 72, 1-3.	0.9	56

#	Article	IF	Citations
55	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). Journal of the National Cancer Institute, 2015, 107, djv261.	3.0	53
56	Income inequality and treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e7-18.e13.	0.8	53
57	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. Journal of Clinical Investigation, 2018, 128, 2979-2995.	3.9	53
58	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
59	HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology, 2020, 6, e196496.	3.4	50
60	Evaluation of HER-2/neu expression in prostatic adenocarcinoma. Cancer, 2002, 95, 1650-1655.	2.0	49
61	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer and Prostatic Diseases, 2019, 22, 420-427.	2.0	49
62	Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 402-402.	0.8	49
63	Racial Disparities in Prostate Cancerâ€“Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	0.9	46
64	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer, 2016, 122, 3127-3135.	2.0	46
65	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	1.3	45
66	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 2006, 66, 1498-1511.	1.2	44
67	A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2010, 28, 4513-4520.	0.8	44
68	Prostate cancer therapy: going forwards by going backwards. Lancet Oncology, The, 2013, 14, 104-105.	5.1	43
69	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncology, 2019, 5, 514.	3.4	43
70	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	1.3	42
71	Definition and Validation of â€œFavorable High-Risk Prostate Cancerâ€• Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.4	40
72	Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Molecular Cancer Therapeutics, 2007, 6, 1736-1744.	1.9	39

#	Article	IF	Citations
73	Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treatment Reviews, 2015, 41, 332-340.	3.4	38
74	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 488-498.	1.6	38
75	Evaluation of diseaseâ€free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trialâ€level metaâ€analysis. Cancer, 2018, 124, 925-933.	2.0	38
76	Event-Free Survival, a Prostate-Specific Antigenâ€“Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. Journal of Clinical Oncology, 2020, 38, 3032-3041.	0.8	37
77	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. European Urology, 2015, 67, 310-318.	0.9	35
78	CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 4503-4503.	0.8	35
79	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery, 2022, 12, 654-669.	7.7	34
80	Elevated insulinâ€like growth factor binding proteinâ€1 (IGFBPâ€1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate, 2014, 74, 225-234.	1.2	33
81	Parthenolide Sensitizes Cells to X-Ray-Induced Cell Killing through Inhibition of NF-ÎºB and Split-Dose Repair. Radiation Research, 2007, 168, 689-697.	0.7	32
82	A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemotherapy and Pharmacology, 2010, 66, 345-356.	1.1	32
83	Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo. Radiation Research, 2017, 187, 501-512.	0.7	32
84	Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. Journal of Clinical Oncology, 2016, 34, 714-720.	0.8	31
85	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 676-676.	0.8	30
86	Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 410-412.	0.9	29
87	Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. Journal of Clinical Oncology, 2019, 37, 765-769.	0.8	29
88	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 837-846.	0.8	29
89	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, LBA5004-LBA5004.	0.8	29
90	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	0.9	28

#	Article	IF	Citations
91	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	2.0	27
92	MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3004-3004.	0.8	27
93	Computational Reconstruction of NFÎºB Pathway Interaction Mechanisms during Prostate Cancer. PLoS Computational Biology, 2016, 12, e1004820.	1.5	27
94	Effect of Celecoxib and the Novel Anti-Cancer Agent, Dimethylamino-Parthenolide, in a Developmental Model of Pancreatic Cancer. Pancreas, 2008, 37, e45-e53.	0.5	26
95	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of Clinical Oncology, 2021, 39, 2486-2496.	0.8	26
96	Inhibition of NF-Îº B and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radical Biology and Medicine, 2011, 51, 2249-2258.	1.3	25
97	Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clinical Cancer Research, 2016, 22, 765-772.	3.2	25
98	When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. European Urology, 2021, 79, 565-567.	0.9	25
99	Suppression of NF-Îº B Activity by Parthenolide Induces X-Ray Sensitivity through Inhibition of Split-Dose Repair in TP53 Null Prostate Cancer Cells. Radiation Research, 2009, 171, 389-396.	0.7	24
100	Association Between Older Age and Increasing Gleason Score. Clinical Genitourinary Cancer, 2015, 13, 525-530.e3.	0.9	23
101	Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 2016, 117, E20-8.	1.3	22
102	Association between CD8 and PDâ€L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate, 2021, 81, 50-57.	1.2	22
103	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 2014, 5, 352-358.	0.5	21
104	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	0.6	21
105	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases, 2018, 21, 306-318.	2.0	21
106	Evaluation of nuclear factor Îº B and chemokine receptor CXCR4 coâ€expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU International, 2011, 108, E51-8.	1.3	20
107	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
108	Approach to Oligometastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 119-129.	1.8	17

#	Article	IF	Citations
109	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	0.8	17
110	Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. European Urology Oncology, 2019, 2, 475-482.	2.6	17
111	Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 348-348.	0.8	17
112	Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detection and Prevention, 2002, 26, 238-244.	2.1	16
113	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factorâ€targeted therapies. Cancer, 2016, 122, 2389-2398.	2.0	16
114	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with â‰¥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	0.5	16
115	Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.. Journal of Clinical Oncology, 2020, 38, 162-162.	0.8	16
116	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 72-82.	1.0	16
117	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 2237-2247.	3.2	16
118	Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Antiâ€“Prostate Cancer Activity. Clinical Cancer Research, 2015, 21, 5578-5587.	3.2	15
119	Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clinical Cancer Research, 2016, 22, 2183-2189.	3.2	15
120	NF-ÎºB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discovery, 2018, 4, 10.	2.0	15
121	Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation TherapyÂ+ Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 130-134.	0.9	15
122	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
123	Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer. Journal of Oncology Practice, 2017, 13, 9-18.	2.5	14
124	Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.. Journal of Clinical Oncology, 2020, 38, 386-386.	0.8	14
125	ECOG: CHAARTED–ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clinical Advances in Hematology and Oncology, 2006, 4, 588-90.	0.3	14
126	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e19-330.e25.	0.8	13

#	Article	IF	Citations
127	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.2	13
128	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	0.6	13
129	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. Journal of Clinical Oncology, 2019, 37, 2961-2967.	0.8	13
130	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. European Urology Focus, 2021, 7, 1130-1136.	1.6	13
131	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	13
132	Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16â€transgenic mice. Drug Development Research, 2019, 80, 824-830.	1.4	12
133	A reproducible approach to high-throughput biological data acquisition and integration. PeerJ, 2015, 3, e791.	0.9	12
134	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 2022, 160, 24-60.	1.3	12
135	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. Journal of Clinical Oncology, 2022, 40, 3011-3014.	0.8	12
136	Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: Meta-analysis of individual participant data from randomized trials.. Journal of Clinical Oncology, 2022, 40, 5070-5070.	0.8	12
137	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	0.9	11
138	Impact of baseline serum ILâ€8 on metastatic hormoneâ€sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate, 2020, 80, 1429-1437.	1.2	11
139	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Network Open, 2021, 4, e2116536.	2.8	11
140	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171.	0.5	11
141	Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell Tumors. Journal of Ultrasound in Medicine, 2015, 34, 1977-1982.	0.8	10
142	Diagnosis and Treatment of Testicular Cancer. Surgical Pathology Clinics, 2015, 8, 717-723.	0.7	10
143	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	2.3	10
144	Risk of prostate cancerâ€specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU International, 2016, 118, 919-926.	1.3	10

#	Article	IF	Citations
145	Age â‰¥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. European Urology Focus, 2017, 3, 621-628.	1.6	10
146	A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 441-448.	1.1	9
147	Management of Metastatic Hormone-Sensitive Prostate Cancer. Current Urology Reports, 2015, 16, 14.	1.0	9
148	A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiotherapy and Oncology, 2020, 152, 80-88.	0.3	9
149	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research, 2020, 26, 6122-6131.	3.2	9
150	NF-ÎºB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. Molecular Cancer Research, 2021, 19, 1137-1145.	1.5	9
151	Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.. Journal of Clinical Oncology, 2019, 37, 5009-5009.	0.8	9
152	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 2018, 16, e233-e242.	0.9	8
153	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136.	1.3	8
154	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 524-532.	2.0	8
155	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 584-590.	1.1	8
156	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer and Prostatic Diseases, 2021, 24, 341-348.	2.0	8
157	Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. Journal of Surgical Research, 2007, 143, 169-176.	0.8	7
158	Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event. Clinical Genitourinary Cancer, 2014, 12, 33-40.e4.	0.9	7
159	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	0.9	7
160	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clinical Genitourinary Cancer, 2019, 17, 58-64.e1.	0.9	7
161	[18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Translational Oncology, 2015, 8, 147-153.	1.7	6
162	AYA testis cancer: The unmet challenge. Pediatric Blood and Cancer, 2019, 66, e27796.	0.8	6

#	Article	IF	Citations
163	Comparison of testis cancerâ€specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU International, 2019, 123, 385-387.	1.3	6
164	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP) Tj ETQq0 0 0 rgBT /Overlock 10 T LBA2-LBA2.	0.8	6
165	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. Prostate Cancer and Prostatic Diseases, 2022, 25, 314-319.	2.0	6
166	Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. Journal of Clinical Oncology, 2022, 40, 5081-5081.	0.8	6
167	Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clinical and Experimental Metastasis, 2018, 35, 649-661.	1.7	5
168	DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiation Research, 2019, 192, 231.	0.7	5
169	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate, 2021, 81, 683-693.	1.2	5
170	Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).. Journal of Clinical Oncology, 2019, 37, 86-86.	0.8	5
171	CT restaging of testicular germ cell tumors: The incidence of isolated pelvic metastases. European Journal of Radiology, 2016, 85, 1439-1444.	1.2	4
172	It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2016, 70, 263-264.	0.9	4
173	Chemotherapy for oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 553-558.	0.9	4
174	A new standard-of-care for advanced-stage disease. Nature Reviews Clinical Oncology, 2017, 14, 592-593.	12.5	4
175	Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clinical Genitourinary Cancer, 2018, 16, 78-84.	0.9	4
176	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castrationâ€resistant prostate cancer. Prostate, 2018, 78, 1053-1062.	1.2	4
177	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 32-37.	0.9	4
178	Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. Molecular Cancer Therapeutics, 2020, 19, 2155-2162.	1.9	4
179	Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 98-98.	0.8	4
180	Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 5057-5057.	0.8	4

#	Article	IF	Citations
181	Metastatic Prostate Cancer: In Search of More Granularity. Journal of Clinical Oncology, 2021, 39, 2968-2969.	0.8	4
182	Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer.. Journal of Clinical Oncology, 2012, 30, 56-56.	0.8	4
183	A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, TPS5090-TPS5090.	0.8	4
184	CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS198-TPS198.	0.8	4
185	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	0.9	4
186	The role of chemotherapy in metastatic prostate cancer. Current Opinion in Urology, 2022, 32, 292-301.	0.9	4
187	First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 377-387.	2.6	4
188	Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. European Urology Focus, 2019, 5, 111-113.	1.6	3
189	Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. European Urology, 2020, 77, 388-390.	0.9	3
190	A Call for Standardized Reporting of Adverse Events. European Urology, 2020, 78, 481-482.	0.9	3
191	Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 199-207.	2.0	3
192	Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 5018-5018.	0.8	3
193	HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.. Journal of Clinical Oncology, 2019, 37, 5020-5020.	0.8	3
194	Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 43-43.	0.8	3
195	Body Mass Index and Outcomes in Germ-Cell Tumors. Clinical Genitourinary Cancer, 2019, 17, 283-290.	0.9	2
196	Selenomethionine induction of DNA repair response in human fibroblasts. , 0, .		2
197	Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors.. Journal of Clinical Oncology, 2019, 37, e16063-e16063.	0.8	2
198	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostateâ€"A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS385-TPS385.	0.8	2

#	Article	IF	Citations
199	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 478-478.	0.8	2
200	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. Journal of Medical Internet Research, 2019, 21, e12044.	2.1	2
201	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 825-832.	0.4	2
202	Association between baseline body mass index and survival in men with metastatic hormoneâ€sensitive prostate cancer: ECOGâ€ACRIN CHAARTED E3805. Prostate, 2022, 82, 1176-1185.	1.2	2
203	Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, 5006-5006.	0.8	2
204	The Case for Systemic Therapy Alone for Prostate Cancer. Journal of Urology, 2006, 176, S42-6.	0.2	1
205	Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. European Urology Focus, 2016, 2, 463-464.	1.6	1
206	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	0.8	1
207	Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?. European Urology, 2018, 74, 420-421.	0.9	1
208	Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort. , 2021, , .		1
209	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4055.	1.7	1
210	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. Journal of Clinical Oncology, 2017, 35, 4585-4585.	0.8	1
211	Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2019, 37, 244-244.	0.8	1
212	Genetic counseling processes and outcomes among prostate cancer patients (ProGen).. Journal of Clinical Oncology, 2019, 37, TPS343-TPS343.	0.8	1
213	Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).. Journal of Clinical Oncology, 2020, 38, 171-171.	0.8	1
214	Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients.. Journal of Clinical Oncology, 2017, 35, 5080-5080.	0.8	1
215	Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5062-5062.	0.8	1
216	The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, 149-149.	0.8	1

#	Article	IF	Citations
217	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€"A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 2022, 40, TPS5103-TPS5103.	0.8	1
218	Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway. Cancer Research, 2022, 82, CT032-CT032.	0.4	1
219	Thymoma and Thymic Carcinoma. , 2006, , 237-256.		0
220	Preface. Hematology/Oncology Clinics of North America, 2013, 27, xi-xii.	0.9	0
221	The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy. JAMA Oncology, 2015, 1, 1270.	3.4	0
222	The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. European Urology, 2019, 76, 729-731.	0.9	0
223	Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2021, 39, 82-82.	0.8	0
224	Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. Journal of Clinical Oncology, 2021, 39, 121-121.	0.8	0
225	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€"A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 2021, 39, TPS266-TPS266.	0.8	0
226	Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.. Journal of Clinical Oncology, 2021, 39, 5076-5076.	0.8	0
227	Use of elevated baseline IL-8, CCL-2, and TNFÎ± to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT).. Journal of Clinical Oncology, 2012, 30, 13-13.	0.8	0
228	Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).. Journal of Clinical Oncology, 2012, 30, 191-191.	0.8	0
229	Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.. Journal of Clinical Oncology, 2017, 35, e16515-e16515.	0.8	0
230	Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.. Journal of Clinical Oncology, 2019, 37, e16508-e16508.	0.8	0
231	Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).. Journal of Clinical Oncology, 2019, 37, e16601-e16601.	0.8	0
232	CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS5591-TPS5591.	0.8	0
233	Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis.. Journal of Clinical Oncology, 2020, 38, 153-153.	0.8	0
234	Circulating tumor (ct)-DNA alterations in patients with testicular germ cell tumors.. Journal of Clinical Oncology, 2020, 38, 415-415.	0.8	0

#	Article	IF	Citations
235	Causes and patterns of mortality in patients with lethal germ cell tumor (GCT).. Journal of Clinical Oncology, 2020, 38, 421-421.	0.8	0
236	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. Journal of Clinical Oncology, 2020, 38, 280-280.	0.8	0
237	Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.. Journal of Clinical Oncology, 2020, 38, 30-30.	0.8	0
238	Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2020, 38, 58-58.	0.8	0
239	Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 174-174.	0.8	0
240	Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.. Journal of Clinical Oncology, 2020, 38, 402-402.	0.8	0
241	Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2011, 2011, 171-176.	1.8	0
242	Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).. Journal of Clinical Oncology, 2022, 40, 145-145.	0.8	0
243	Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.. Journal of Clinical Oncology, 2022, 40, 146-146.	0.8	0
244	Reply to L. Marandino et al. Journal of Clinical Oncology, 2022, , JCO2200497.	0.8	0